ARWR - Arrowhead Pharmaceuticals

-

$undefined

N/A

(N/A)

Arrowhead Pharmaceuticals NasdaqGS:ARWR Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.

Location: 177 East Colorado Boulevard, Suite 700, Pasadena, CA, 91105, United States | Website: https://arrowheadpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.969B

Cash

1.095B

Avg Qtr Burn

N/A

Short % of Float

10.95%

Insider Ownership

13.02%

Institutional Own.

77.24%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Plozasiran (ARO-APOC3) Details
Familial chylomicronemia syndrome

PDUFA

Approval decision

Plozasiran (ARO-APOC3) Details
Severe hypertriglyceridemia

Phase 3

Data readout

Fazirsiran (ARO-AAT) (TAK-999) Details
Severe alpha-1 antitrypsin deficiency, Liver disease

Phase 3

Update

Phase 3

Initiation

Phase 2b

Update

ARO-ANG3 Details
Dyslipidemia

Phase 2

Update

ARO-DM1 Details
Myotonic Dystrophy Type 1

Phase 1/2

Data readout

ARO-INHBE Details
Obesity, Metabolic disorder

Phase 1/2

Data readout

ARO-CFB Details
Complement mediated diseases, Kidney disease, IgA nephropathy

Phase 1/2

Data readout

ARO-C3 (RNAi) Details
Paroxysmal nocturnal hemoglobinuria , Renal disease, IgA nephropathy, C3 Glomerulopathy

Phase 1/2

Data readout

ARO-MMP7 Details
Idiopathic pulmonary fibrosis

Phase 1/2

Data readout

ARO-MUC5AC Details
Lung disease, Muco-Obstructive Lung Diseases

Phase 1/2

Data readout

ARO-RAGE Details
Muco-Obstructive Lung Diseases, Inflammatory disease, Asthma

Phase 1/2

Update

Phase 1/2

Initiation

ARO-DUX4 Details
Facioscapulohumeral muscular dystrophy

Phase 1/2

Initiation

Failed

Discontinued

ARO-HSD Details
Liver disease, Non-alcoholic steatohepatitis

Failed

Discontinued